Home » Stocks » ADVM

Adverum Biotechnologies, Inc. (ADVM)

Stock Price: $2.38 USD 0.01 (0.42%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 232.11M
Revenue (ttm) 7.50M
Net Income (ttm) -123.04M
Shares Out 97.75M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $2.38
Previous Close $2.37
Change ($) 0.01
Change (%) 0.42%
Day's Open 2.37
Day's Range 2.33 - 2.53
Day's Volume 2,418,892
52-Week Range 2.26 - 19.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- Based on latest analyses, company is revising ADVM-022 development plan to focus on  wet AMD and low doses (2 x 10^11 vg/eye and lower);  no longer planning development for DME -- -- Company to host ...

1 week ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 month ago - Zacks Investment Research

-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --

1 month ago - GlobeNewsWire

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...

Other stocks mentioned: CLBS, IFRX
1 month ago - GuruFocus

The uncertainty over the biotech's lead clinical asset weighed on its shares last month.

1 month ago - The Motley Fool

Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

2 months ago - Zacks Investment Research

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: ADT, INFN, KOS, SWN
2 months ago - 24/7 Wall Street

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 months ago - Business Wire

REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...

2 months ago - GlobeNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 months ago - Business Wire

NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors are advi...

2 months ago - PRNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 months ago - Business Wire

REDWOOD CITY, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies Inc. (“Adverum”) (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare dis...

2 months ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

REDWOOD CITY, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, toda...

2 months ago - GlobeNewsWire

Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%, t...

Other stocks mentioned: AKBA
2 months ago - GuruFocus

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 months ago - Business Wire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

2 months ago - Business Wire

Adverum Biotechnologies Inc (NASDAQ: ADVM) has announced new long-term data from the OPTIC Phase 1 trial of ADVM-022 single intravitreal (IVT) injection gene therapy in patients with neovascular or wet ...

2 months ago - Benzinga

-- Long-term durability and maintained efficacy; sustained robust aflibercept protein expression observed -- -- 60% of patients injection free beyond 1 year following 2 x 10^11 single dose --

2 months ago - GlobeNewsWire

Adverum Biotechnologies (NASDAQ: ADVM) shares are trading lower after the company announced a Suspected Unexpected Serious Adverse Reaction of hypotony in its INFINITY clinical trial evaluating ADVM-022...

3 months ago - Benzinga

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

3 months ago - Business Wire

Investors are running for the hills following the company's latest clinical update.

3 months ago - The Motley Fool

REDWOOD CITY, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant d...

3 months ago - GlobeNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

3 months ago - Business Wire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

3 months ago - Business Wire

Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum's Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D.

3 months ago - GlobeNewsWire

Sonic's Nominees Lack Experience and Qualifications to Advance Adverum's Commercialization Progress or Deliver Global Access to Vision-Saving Gene Therapy

3 months ago - GlobeNewsWire

HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Company” or...

3 months ago - Business Wire

-- Adverum to host webcast with key opinion leaders on  Sunday, May 2, 2021 at 7:00 AM PT --  REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a cli...

3 months ago - GlobeNewsWire

HONOLULU, April 8, 2021 /PRNewswire/ -- The Sonic Fund II, L.P. ("Sonic"), which beneficially owns approximately 6.7% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the...

3 months ago - PRNewsWire

-- Anand Reddi appointed vice president, patient advocacy, access, and  digital innovation -- -- Bill Tan, PharmD, appointed vice president,  clinical operations program lead --

3 months ago - GlobeNewsWire

REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to...

4 months ago - GlobeNewsWire

Responds to Intent to Nominate Directors from Sonic Fund

4 months ago - GlobeNewsWire

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of -21.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the s...

4 months ago - Zacks Investment Research

-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA --

4 months ago - GlobeNewsWire

Key Opinion Leader Arshad M. Khanani, M.D., M.A., director of clinical research, Sierra Eye Associates, and OPTIC and INFINITY trial investigator will participate on this call Key Opinion Leader Arshad ...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

5 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

5 months ago - GlobeNewsWire

Adverum Biosciences stock, a clinical stage gene therapy company focused on serious ocular and rare diseases, has rallied by a solid 18% over the last 5 trading days, after the company disclosed in regu...

6 months ago - Forbes

Adverum Biotechnologies (ADVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

-- 174,000-square-foot commercial GMP facility in Durham, NC for the manufacturing of ADVM-022, an intravitreal gene therapy in development for wet AMD and DME -- -- Multiple production suites with tota...

6 months ago - GlobeNewsWire

REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, tod...

8 months ago - GlobeNewsWire

-- Maintained efficacy and greatly reduced anti-VEGF treatment burden after  a single IVT injection of ADVM-022 -- -- R obust preliminary aqueous a nti-VEGF protein expression observed at 18 months in C...

8 months ago - GlobeNewsWire

Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 11.43% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

8 months ago - Zacks Investment Research

-- Dr. Carl Regillo to present OPTIC data a t the R etina S ubspecialty D ay on  Friday, November 13, 2020 at 2:15 pm PT -- -- Company to host webcast with key opinion leaders on Saturday , November 14 ...

9 months ago - GlobeNewsWire

About ADVM

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 31, 2014
CEO
Leone Patterson
Employees
167
Stock Exchange
NASDAQ
Ticker Symbol
ADVM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for ADVM stock is "Buy." The 12-month stock price forecast is 7.88, which is an increase of 231.09% from the latest price.

Price Target
$7.88
(231.09% upside)
Analyst Consensus: Buy